Redeye: BioInvent Q2 2023 - Progress on all Fronts
Since our last update, new readouts have been published with BI-1808 and BI-1206 in solid tumours. We review these results and the near-term outlook of the project portfolio. In particular, we expect news about the subcutaneous version of BI-1206 soon, which will be key to its future development.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/